Biogen calls for discussion on biggest ever MS study

Biogen (Nasdaq: BIIB) is preparing to present research collected from more than 16,000 multiple sclerosis (MS) patients across Europe, the largest study to capture the widespread impact of the disease.

The US biotech major will also provide an update on clinical findings from the company’s broad portfolio of MS therapies at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London next week.

The Biogen-sponsored MS Cost of Illness (COI) study further builds on the highly influential and frequently cited 2005 European COI study, which examined the burden of MS on patients and their caregivers in Europe.